The interest rate on borrowings. [Refer: Borrowings]

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 7
-IssueDate 2024-01-01
-Paragraph 7
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_BorrowingsInterestRate
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ContractualCapitalCommitments
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.

+ References

+ Details

Name:	ifrs-full_CurrentPrepaidExpenses
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of non-current financial liabilities. [Refer: Financial liabilities]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2024-01-01
-Paragraph 25
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_NoncurrentFinancialLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.

+ References

+ Details

Name:	ifrs-full_NotionalAmount
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash inflow from borrowings obtained. [Refer: Borrowings]

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2024-01-01
-Paragraph 17
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProceedsFromIssueOfOrdinaryShares
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph d
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_d&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2024-01-01
-Paragraph 50
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_a&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_UndrawnBorrowingFacilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Borrowings, Cumulative Milestone Prepayment Amount

+ References

No definition available.

+ Details

Name:	nbx_BorrowingsCumulativeMilestonePrepaymentAmount
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Borrowings, Milestone Payment Contigency

+ References

No definition available.

+ Details

Name:	nbx_BorrowingsMilestonePaymentContigency
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Borrowings, Milestone Payment, First Installment Period

+ References

No definition available.

+ Details

Name:	nbx_BorrowingsMilestonePaymentFirstInstallmentPeriod
Namespace Prefix:	nbx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Borrowings, Milestone Payment, Second Installment Period

+ References

No definition available.

+ Details

Name:	nbx_BorrowingsMilestonePaymentSecondInstallmentPeriod
Namespace Prefix:	nbx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Borrowings, Net Sales Threshold

+ References

No definition available.

+ Details

Name:	nbx_BorrowingsNetSalesThreshold
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Borrowings, Prorated Payment, Maximum Percentage Of Milestone Payment

+ References

No definition available.

+ Details

Name:	nbx_BorrowingsProratedPaymentMaximumPercentageOfMilestonePayment
Namespace Prefix:	nbx_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Borrowings, Remaining Notional Amount

+ References

No definition available.

+ Details

Name:	nbx_BorrowingsRemainingNotionalAmount
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration Agreement, Collected

+ References

No definition available.

+ Details

Name:	nbx_CollaborationAgreementCollected
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration Agreement, Equity Investment Compensation

+ References

No definition available.

+ Details

Name:	nbx_CollaborationAgreementEquityInvestmentCompensation
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration Agreement, Potential Milestones Payments To Be Received

+ References

No definition available.

+ Details

Name:	nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication

+ References

No definition available.

+ Details

Name:	nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration Agreement, Success-Based Payment

+ References

No definition available.

+ Details

Name:	nbx_CollaborationAgreementSuccessBasedPayment
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration Agreement, Upfront Payment License Fee

+ References

No definition available.

+ Details

Name:	nbx_CollaborationAgreementUpfrontPaymentLicenseFee
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration Agreement, Upfront Payment Received

+ References

No definition available.

+ Details

Name:	nbx_CollaborationAgreementUpfrontPaymentReceived
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contractual Commitments, Cumulative Payments

+ References

No definition available.

+ Details

Name:	nbx_ContractualCommitmentsCumulativePayments
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contractual Commitments, Milestone Payment, Annual Increase

+ References

No definition available.

+ Details

Name:	nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports

+ References

No definition available.

+ Details

Name:	nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contractual Commitments, Milestone Payment Upon Second Regulatory Approval

+ References

No definition available.

+ Details

Name:	nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contractual Commitments, Payment

+ References

No definition available.

+ Details

Name:	nbx_ContractualCommitmentsPayment
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Interest Payable, Payment-In-Kind

+ References

No definition available.

+ Details

Name:	nbx_InterestPayablePaymentInKind
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone Payment, Deferment Period After Enrollment

+ References

No definition available.

+ Details

Name:	nbx_MilestonePaymentDefermentPeriodAfterEnrollment
Namespace Prefix:	nbx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Patients In Clinical Trial

+ References

No definition available.

+ Details

Name:	nbx_NumberOfPatientsInClinicalTrial
Namespace Prefix:	nbx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Proceeds From Milestone Payment

+ References

No definition available.

+ Details

Name:	nbx_ProceedsFromMilestonePayment
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalties Agreement, Period

+ References

No definition available.

+ Details

Name:	nbx_RoyaltiesAgreementPeriod
Namespace Prefix:	nbx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	nbx_EventAxis=nbx_EventOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	nbx_EventAxis=nbx_EventTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	nbx_TranchesAxis=nbx_FirstTrancheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	nbx_TranchesAxis=nbx_SecondTrancheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementTrancheTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbx_NanobiotixCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant transactions (Details) € in Thousands, $ in Thousands									1 Months Ended				12 Months Ended
	Jan. 29, 2024 USD ($)	Dec. 22, 2023 EUR (€)	Dec. 04, 2023 USD ($)	Jul. 07, 2023 USD ($)	Oct. 18, 2022 EUR (€)	Jan. 01, 2021	Feb. 03, 2020 USD ($)	Dec. 21, 2018 USD ($)	Jun. 30, 2021 USD ($) patient	Mar. 31, 2019 EUR (€)	Jan. 31, 2019	Oct. 31, 2018 EUR (€)	Dec. 31, 2024 EUR (€)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2024 USD ($)	Dec. 22, 2023 USD ($)	Oct. 12, 2023 EUR (€)	Jul. 19, 2023 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Jul. 31, 2018 EUR (€)
Disclosure of transactions between related parties [line items]
Milestone payment upon second regulatory approval \| $																							$ 750
Increase in loans and conditional advances \| €													€ 0		€ 150	€ 0
Loans repayments \| €													3,075		2,971	3,642
Prepaid expenses \| €													3,195		2,560
Capital increases \| €													0		60,154	€ 0
Non-current financial liabilities \| €													45,978		€ 45,543
EIB fixed rate loan
Disclosure of transactions between related parties [line items]
Increase in loans and conditional advances \| €										€ 14,000		€ 16,000
Borrowings, interest rate										5.00%		6.00%			21.30%	21.30%
Undrawn borrowing facilities \| €																								€ 10,000
Royalties agreement, period					6 years	6 years
Remaining notional amount \| €					€ 25,300
Net sales threshold \| €					5,000
Accrued interest \| €					5,400																	€ 5,400
Milestone payment \| €					€ 20,000																	20,000
First installment period					1 year
Second installment period					2 years
Prorated payment, maximum percentage of milestone payment					10.00%
Borrowings, cumulative milestone prepayment amount \| €																						€ 100,000
Loans repayments \| €													200		€ 800
Non-current financial liabilities \| €													€ 19,000		19,200	€ 27,500
Maximum \| Event One
Disclosure of transactions between related parties [line items]
Milestone payment increase \| $																			$ 2,200
Maximum \| Event Two
Disclosure of transactions between related parties [line items]
Milestone payment increase \| $																			$ 16,400
First Tranche \| EIB fixed rate loan
Disclosure of transactions between related parties [line items]
Borrowings, interest rate					6.00%
Remaining notional amount \| €					€ 16,000
Second Tranche \| EIB fixed rate loan
Disclosure of transactions between related parties [line items]
Borrowings, interest rate					5.00%
Remaining notional amount \| €					€ 9,300
Second Tranche \| EIB fixed rate loan, tranche two
Disclosure of transactions between related parties [line items]
Remaining notional amount \| €					€ 9,300
Top of Range \| EIB fixed rate loan
Disclosure of transactions between related parties [line items]
Notional amount \| €																										€ 40,000
Maximum \| EIB fixed rate loan
Disclosure of transactions between related parties [line items]
Notional amount \| €																										€ 40,000
Janssen
Disclosure of transactions between related parties [line items]
Collaboration agreement, upfront payment license fee \| $				$ 30,000
Collaboration agreement, success-based payment \| $				1,800,000
Proceeds from milestone payment \| $	$ 20,000
Collaboration agreement, equity investment receivable \| $			$ 4,800	20,200
Capital increases \| $				30,000
Janssen \| EIB fixed rate loan
Disclosure of transactions between related parties [line items]
Borrowings, interest rate													21.30%							21.30%
Janssen \| First Tranche
Disclosure of transactions between related parties [line items]
Collaboration agreement, equity investment receivable \| $				5,000
Janssen \| Second Tranche
Disclosure of transactions between related parties [line items]
Collaboration agreement, equity investment receivable \| $				25,000
Janssen \| Top of Range
Disclosure of transactions between related parties [line items]
Potential development and commercial milestones payments \| $				650,000
Collaboration agreement, compensation per indication \| $				220,000
Janssen \| Nanobiotix Corp. \| Top of Range
Disclosure of transactions between related parties [line items]
Collaboration agreement, compensation per indication \| $				$ 220,000
LianBio, NBTXR3
Disclosure of transactions between related parties [line items]
Upfront payment received \| $									$ 20,000									$ 20,000
Collaboration agreement, amount collected \| €													€ 1,100
Upfront payment \| €		€ 20,000
LianBio, NBTXR3 \| Maximum
Disclosure of transactions between related parties [line items]
Potential development and commercial milestones payments \| $									$ 205,000
LianBio, NBTXR3 \| Maximum
Disclosure of transactions between related parties [line items]
Potential development and commercial milestones payments \| $																					$ 225,000				$ 205,000
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3
Disclosure of transactions between related parties [line items]
Upfront payment \| $																		$ 6,500
Contractual commitments, cumulative payments \| $																									$ 6,500
Milestone payment upon second regulatory approval \| $																				$ 5,000
Royalties agreement, period													10 years	10 years
Milestone payment upon receipt of clinical study reports \| $														$ 1,000			$ 1,000
MD Anderson Cancer Center, NBTXR3
Disclosure of transactions between related parties [line items]
Upfront payment \| $							$ 1,000	$ 1,000
Number of patients \| patient									312
Contractual capital commitments \| $								$ 11,000
Milestone payment, deferment period											6 months
Prepaid expenses \| €													€ 1,200		€ 1,200